Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $207.00 at Citigroup

Ascendis Pharma A/S (NASDAQ:ASND) had its target price boosted by Citigroup from $178.00 to $207.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Other analysts also recently issued research reports about the company. Oppenheimer reiterated an outperform rating and set a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday. JPMorgan Chase & Co. cut their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating for the company in a research note on Wednesday, September 4th. TD Cowen lowered their price objective on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a buy rating on the stock in a research report on Wednesday, September 4th. Jefferies Financial Group upped their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a buy rating in a research report on Tuesday, August 13th. Finally, The Goldman Sachs Group raised their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a buy rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $193.77.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $151.26 on Tuesday. The company has a market capitalization of $8.81 billion, a PE ratio of -15.97 and a beta of 0.63. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The business’s fifty day moving average is $133.30 and its 200 day moving average is $136.64.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP bought a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $78,719,000. Price T Rowe Associates Inc. MD increased its stake in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the period. Acadian Asset Management LLC raised its holdings in Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after buying an additional 234,446 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after buying an additional 229,995 shares during the period. Finally, Westfield Capital Management Co. LP grew its holdings in Ascendis Pharma A/S by 6.0% in the 4th quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company’s stock worth $507,658,000 after acquiring an additional 228,457 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.